tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Nuvilex'

Nuvilex Announces Name Change to PharmaCyte Biotech

Nuvilex Announces Name Change to PharmaCyte Biotech

Company’s Shares Will Trade Under New Ticker Symbol PHCB

SILVER SPRING, MD., Jan. 7, 2015 — Nuvilex, Inc. (NVLX) today announced that the Company has changed its name to PharmaCyte Biotech, Inc. Shares in PharmaCyte Biotech will trade under the new ticker symbol “PHCB” on the OTCQB electronic platform. The new symbol is expected to become effective at the open of the market on January 8, 2014. The name change ...

Read More →
0

Nuvilex Announces Preliminary Data from Preclinical Study of Effects of its Pancreatic Cancer Treatment on Ascites Fluid Formation

SILVER SPRING, MD, November 19, 2014 – Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that promising preliminary data has been released from the preclinical animal study on the effects of Nuvilex’s pancreatic cancer treatment on the accumulation of ascites fluid in tumor-bearing animals. This study, performed by Nuvilex contractor, Translational Drug Development (TD2), employed immunosuppressed mice implanted with disseminated human ovarian cancer cells into the peritoneal cavity.

Preliminary ...

Read More →
0

Nuvilex, Inc. Engaged in “Cutting Edge” Cannabis Preclinical Studies Using Model Compounds with Cell-in-a-Box

Written by Ι Stock Market Media Group Staff — October 29, 2014

New York, NY – Nuvilex, Inc. (OTCQB: NVLX) isn’t letting the upcoming mid-term elections or the views in Washington, D.C., on medical marijuana slow down its research.  The company is currently engaged in preclinical studies at the University of Northern Colorado (UNC) targeting Cannabis-based cancer treatments using Nuvilex’s Cell-in-a-Box® cellulose-based live cell encapsulation technology. 

While waiting for a Schedule 1 license from the DEA in order to conduct research using marijuana, Dr. ...

Read More →
0

Nuvilex, Inc. Moves Closer to “Bio-Artificial Pancreas” Diabetes Treatment with License for Insulin-Producing Cells

Written by Ι Stock Market Media Group Staff — October 21, 2014

Nuvilex, Inc. (OTCQB: NVLX) has carefully mapped out its plan to develop a diabetes treatment using the Cell-in-a-Box® platform technology.  It started in November 2013 when the company acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes.  This acquisition gave Nuvilex a proven delivery system with which it could firmly plant its flag in the race for a diabetes treatment.

Now, almost ...

Read More →
0

Nuvilex Contracts with University of Veterinary Medicine in Vienna to Conduct Preclinical Studies to Develop Diabetes Treatment

SILVER SPRING, MD, October 20, 2014 – Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into a Collaborative Research Agreement (CRA) with the University of Veterinary Medicine in Vienna, Austria (University). The CRA calls for the University to perform “in vitro” and animal studies that use the Cell-in-a-Box® cellulose-based live cell encapsulation technology to develop a new treatment for insulin-dependent diabetes. Nuvilex has ...

Read More →
0

Nuvilex Secures Worldwide License for Insulin-Producing Cells for Use in Developing Diabetes Treatment

SILVER SPRING, Md., Oct. 16, 2014 — Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into a license with the University of Technology in Sydney, Australia (UTS), that grants Nuvilex the worldwide rights to use human insulin-producing cells, termed “Melligen” cells, developed by Prof. Ann Simpson and her colleagues at UTS for the development of a treatment for insulin-dependent (Type 1 or ...

Read More →
0
Page 1 of 8 12345...»
ContactUs.com